




GATA3 - clone L50-823 (mouse) most sensitive marker for breast and urothelial carcinoma

- nuclear staining (transcription factor)
- GATA3 is an important regulator of luminal differentiation of breast epithelial cells
- breast cancer: GATA3 is significantly more sensitive than mammaglobin and GCDFP-15⁵⁻¹²
- urothelial carcinoma: GATA3 is more sensitive than p63, particularly in invasive and poorly differentiated tumors¹³⁻¹⁸
- carcinoma of unknown primary (CUP): GATA3 positivity indicates breast or bladder origin^{5,7,8,13,17}

Ordering Information GATA3, clone L50-823 (mouse)

Available sizes:

0.1 ml concentrate
0.5 ml concentrate
1.0 ml concentrate
1.0 ml predilute ready-to-use
7.0 ml predilute ready-to-use
5 positive control slides

Cat. No.

390M-14
390M-15
390M-16
390M-17
390M-18
390S

IVD CE

GATA3 References

Reviews

1. Asch-Kendrick R, Cimino-Mathews A. The role of GATA3 in breast carcinomas: a review. *Hum Pathol* 2016; 48: 37-47.
2. Miettinen M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. *Am J Pathol* 2014; 38: 13-22.
3. Ordóñez NG. Value of GATA3 immunostaining in tumor diagnosis: a review. *Adv Anat Pathol* 2013; 20: 352-360.
4. Takaku M, et al. GATA3 in breast cancer: tumor suppressor or oncogene? *Gene Expr* 2015; 16: 163-168.

Gynaecopathology

5. Davis DG, et al. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. *Hum Pathol* 2016; 47: 26-31.
6. McCleskey BC, et al. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse. *Am J Clin Pathol* 2015; 144: 756-763.
7. Lew M, et al. The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. *Cancer Cytopathol* 2015; 123: 576-581.
8. Deftereos G, et al. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. *Am J Surg Pathol* 2015; 39: 1282-1289.
9. Krings G, et al. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. *Hum Pathol* 2014; 45: 2225-2232.
10. Hisamatsu Y, et al. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. *Breast Cancer* 2015; 22: 520-528.
11. Banet N, et al. GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. *Am J Surg Pathol* 2015; 39: 101-108.
12. Howitt BE, et al. GATA3 is a sensitive and specific marker of benign and malignant mesonephric lesions in the lower female genital tract. *Am J Surg Pathol* 2015; 39: 1411-1419.

Uropathology

13. Amin MB, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. *Am J Surg Pathol* 2014; 38: e20-34.
14. Tian W, et al. Utility of uroplakin II expression as a marker of urothelial carcinoma. *Hum Pathol* 2015; 46: 58-64.
15. Mohanty SK, et al. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas. *Am J Clin Pathol* 2014; 142: 173-183.
16. Zhao L, et al. Is GATA3 expression maintained in regional metastases? A study of paired primary and metastatic urothelial carcinomas. *Am J Surg Pathol* 2013; 37: 1876-1881.
17. Brandler TC, et al. Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic urothelial carcinoma in cytology specimens. *Cancer Cytopathol* 2014; 122: 468-473.
18. Siddiqui MT, et al. GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: a review of 25 cases. *Diagn Cytopathol* 2014; 42: 809-815.

First-hand information
www.medac-diagnostika.de

